MedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in “Take Advantage of the Moment” Episode HOLLAND, Mich., July 11, 2024 – MedTech Gurus, a leading podcast focused on the forefront of medical technology, featured Oncocyte Corporation (NASDAQ: OCX) CEO Josh Riggs in its latest episode, “Take Advantage of the Moment.
OncoCyte Announces Andrea James as New CFO and Principal Officer OncoCyte (OCX) just unveiled an announcement. Oncocyte Corporation has appointed Andrea James as their new Chief Financial Officer and Principal Fi…
Oncocyte Appoints Andrea James as Chief Financial Officer IRVINE, Calif., June 17, 2024 – Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that it has appointed leading finance executive, Andrea James, to the position of Chief Financial Officer.
Oncocyte Appoints Andrea James as Chief Financial Officer IRVINE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that it has appointed leading finance executive, Andrea James, to the position of Chief Financial Officer.
Breakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte's VitaGraft Study NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Oncocyte's (Nasdaq: OCX) VitaGraft Kidney™ diagnostic test for transplant monitoring has shown promising results in a Phase 2 clinical trial, published in the prestigious New England Journal of Medicine. The trial evaluated the test's effectiveness in monitoring graft health in patients with antibody-mediated rejection (AMR), a leading cause of kidney transplant failure.
OncoCyte Executive Team Receives Significant Salary Increases OncoCyte (OCX) has issued an update. Oncocyte Corporation’s Board of Directors, following the Compensation Committee’s advice, has agreed to signif…
Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine | OCX Stock News Oncocyte''s VitaGraft Kidney test shows promising results in NEJM for monitoring graft injury and AMR in kidney transplants. Learn more about this groundbreaking study.
Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine IRVINE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that favorable data regarding its lead product VitaGraft™ Kidney was published in the New England Journal of Medicine . Oncocyte's Drs. Ekke Schuetz and Julia Beck, inventors of the technology, are among the authors of the study. VitaGraft Kidney was used to monitor graft injury in a phase 2 double-blind, placebo-controlled study ( NCT05021484 ) of the investigational drug felzartamab, a fully human CD38 monoclonal antibody, for antibody-mediated rejection (AMR), a leading cause of kidney allograft failure.
OncoCyte Corp (OCX) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges and ... OncoCyte Corp (OCX) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges and Seizing Growth Opportunities
OncoCyte Corporation (OCX) Q1 2024 Earnings Call Transcript OncoCyte Corporation (NASDAQ:OCX ) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Jeff Ramson - Investor Relations Josh Riggs - President and Chief Executive Officer Conference Call Participants Mike Matson - Needham Mason Carrico - Stephens Operator Good afternoon. My name is Briana and I will be your conference operator today.